|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: new opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain A, Dubashi B, Reddy KS and Jain P:
Weekly paclitaxel in ovarian cancer - the latest success story.
Curr Oncol. 18:16–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar S, Mahdi H, Bryant C, Shah JP, Garg
G and Munkarah A: Clinical trials and progress with paclitaxel in
ovarian cancer. Int J Womens Health. 2:411–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar
|
|
6
|
Bijman MN, Hermelink CA, van Berkel MP,
Laan AC, Janmaat ML, Peters GJ and Boven E: Interaction between
celecoxib and docetaxel or cisplatin in human cell lines of ovarian
cancer and colon cancer is independent of COX-2 expression levels.
Biochem Pharmacol. 75:427–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Munkarah AR, Ali-Fehmi R, Jiang JZ,
Elhammady E, Malone JM Jr and Saed GM: The effects of combining
docetaxel and cyclooxygenase-2 inhibitors on proliferation and
apoptosis in epithelial ovarian cancer. Anticancer Drugs.
18:889–896. 2007.PubMed/NCBI
|
|
8
|
Vane JR, Bakhle YS and Botting RM:
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120.
1998. View Article : Google Scholar
|
|
9
|
Smith WL, Garavito RM and DeWitt DL:
Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2.
J Biol Chem. 271:33157–33160. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Ji ZL, Zhuo GC, Xu RJ, Wang J and
Jiang HR: Effects of a selective cyclooxygenase-1 inhibitor in
SKOV-3 ovarian carcinoma xenograft-bearing mice. Med Oncol.
27:98–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dore M, Cote LC, Mitchell A and Sirois J:
Expression of prostaglandin G/H synthase type 1, but not type 2, in
human ovarian adenocarcinomas. J Histochem Cytochem. 46:77–84.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daikoku T, Wang D, Tranguch S, Morrow JD,
Orsulic S, DuBois RN and Dey SK: Cyclooxygenase-1 is a potential
target for prevention and treatment of ovarian epithelial cancer.
Cancer Res. 65:3735–3744. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daikoku T, Tranguch S, Trofimova IN,
Dinulescu DM, Jacks T, Nikitin AY, Connolly DC and Dey SK:
Cyclooxygenase-1 is overexpressed in multiple genetically
engineered mouse models of epithelial ovarian cancer. Cancer Res.
66:2527–2531. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daikoku T, Tranguch S, Chakrabarty A, Wang
D, Khabele D, Orsulic S, Morrow JD, Dubois RN and Dey SK:
Extracellular signal-regulated kinase is a target of
cyclooxygenase-1-peroxisome proliferator-activated receptor-delta
signaling in epithelial ovarian cancer. Cancer Res. 67:5285–5292.
2007. View Article : Google Scholar
|
|
15
|
Gupta RA, Tejada LV, Tong BJ, Das SK,
Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed
and promotes angiogenic growth factor production in ovarian cancer.
Cancer Res. 63:906–911. 2003.PubMed/NCBI
|
|
16
|
Reese J, Zhao X, Ma WG, Brown N, Maziasz
TJ and Dey SK: Comparative analysis of pharmacologic and/or genetic
disruption of cyclooxygenase-1 and cyclooxygenase-2 function in
female reproduction in mice. Endocrinology. 142:3198–3206.
2001.PubMed/NCBI
|
|
17
|
Williams CS, Watson AJM, Sheng H, Helou R,
Shao J and DuBois RN: Celecoxib prevents tumor growth in vivo
without toxicity to normal gut: lack of correlation between in
vitro and in vivo models. Cancer Res. 60:6045–6051. 2000.PubMed/NCBI
|
|
18
|
Seki A, Kodama J, Miyagi Y, Kamimura S,
Yoshinouchi M and Kudo T: Amplification of the mdm-2 gene and p53
abnormalities in uterine sarcomas. Int J Cancer. 73:33–37. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Xu RJ, Jiang LH, Shi JF, Long X and
Fan B: Expression of cyclooxygenase-2 and inducible nitric oxide
synthase correlates with tumor angiogenesis in endometrial
carcinoma. Med Oncol. 22:63–70. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis: a new significant and independent prognostic
indicator in early-stage breast carcinoma. J Natl Cancer Inst.
84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kitamura T, Itoh M, Noda T, Matsuura M and
Wakabayashi K: Combined effects of cyclooxygenase-1 and
cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis
in adenomatous polyposis coli gene knockout mice. Int J Cancer.
109:576–580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrara N, Leung DW, Cachianes G, Winer J
and Henzel WL: Purification and cloning of vascular endothelial
growth factor secreted by pituitary folliculostellate cells.
Methods Enzymol. 198:391–405. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bernard MP, Bancos S, Sime PJ and Phipps
RP: Targeting cyclooxygenase-2 in hematological malignancies:
rationale and promise. Curr Pharm Des. 14:2051–2060. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ali-Fehmi R, Che M, Khalifeh I, Malone JM,
Morris R, Lawrence WD and Munkarah AR: The effect of
cyclooxygenase-2 expression on tumor vascularity in advanced stage
ovarian serous carcinoma. Cancer. 98:1423–1429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khunnarong J, Tangjitgamol S,
Manusirivithaya S, Suekwattana P and Leelahakorn S: Expression of
cyclooxygenase-1 in epithelial ovarian cancer: a
clinicopathological study. Asian Pac J Cancer Prev. 9:757–762.
2008.PubMed/NCBI
|
|
26
|
Urick ME, Giles JR and Johnson PA: VEGF
expression and the effect of NSAIDs on ascites cell proliferation
in the hen model of ovarian cancer. Gynecol Oncol. 110:418–424.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Wang J, Jiang HR, Xu XL, Zhang J,
Liu ML and Zhai LY: Combined effects of cyclooxygenase-1 and
cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.
Int J Mol Sci. 12:668–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harlozinska A, Sedlaczek P, Kulpa J,
Grybos M, Wójcik E, Van Dalen A and Einarsson R: Vascular
endothelial growth factor (VEGF) concentration in sera and tumor
effusions from patients with ovarian carcinoma. Anticancer Res.
24:1149–1157. 2004.PubMed/NCBI
|
|
29
|
Prager GW and Poettler M: Angiogenesis in
cancer. Basic mechanisms and therapeutic advances. Hamostaseologie.
32:Aug 12–2011.(Epub ahead of print).
|
|
30
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Senger DR, Van de Water L, Brown LF, Nagy
JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF:
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer
Metastasis Rev. 12:303–324. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Wang L, Zhang W, Tang B, Zhang J,
Song H, Yao D, Tang Y, Chen X, Yang Z, et al: Correlation of serum
VEGF levels with clinical stage, therapy efficacy, tumor metastasis
and patient survival in ovarian cancer. Anticancer Res.
24:1973–1979. 2004.PubMed/NCBI
|
|
33
|
Yamamoto S, Konishi I, Mandai M, Kuroda H,
Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular
endothelial growth factor (VEGF) in epithelia ovarian neoplasms:
correlation with clinicopathology and patient survival and analysis
of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Rahden BH, Stein HJ, Pühringer F, Koch
I, Langer R, Piontek G, Siewert JR, Höfler H and Sarbia M:
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular
endothelial growth factors (VEGF-A, VEGF-C) in esophageal
adenocarcinoma. Cancer Res. 65:5038–5044. 2005.PubMed/NCBI
|
|
35
|
Li W, Xu RJ, Lin ZY, Zhuo GC and Zhang HH:
Effects of a cyclooxygenase-1-selective inhibitor in a mouse model
of ovarian cancer, administered alone or in combination with
ibuprofen, a nonselective cyclooxygenase inhibitor. Med Oncol.
26:170–177. 2009. View Article : Google Scholar
|
|
36
|
Li Y, Guo Z, Han YP and Guo XY:
Expressions of MVD, VEGF, Ki67 in residual prostate cancer after
cryoablation. Clin Oncol Cancer Res. 8:27–32. 2011.
|
|
37
|
Zhou YJ, Xiong YX, Wu XT, Shi D, Fan W,
Zhou T, Li YC and Huang X: Inactivation of PTEN is associated with
increased angiogenesis and VEGF overexpression in gastric cancer.
World J Gastroenterol. 10:3225–3229. 2004.PubMed/NCBI
|
|
38
|
Wang J, Lv F, Fei X, Cui Q, Wang L, Gao X,
Yuan Z, Lin Q, Lv Y and Liu A: Study on the characteristics of
contrast-enhanced ultrasound and its utility in assessing the
microvessel density in ovarian tumors or tumor-like lesions. Int J
Biol Sci. 7:600–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goodheart MJ, Ritchie JM, Rose SL,
Fruehauf JP, De Young BR and Buller RE: The relationship of
molecular markers of p53 function and angiogenesis to prognosis of
stage I epithelial ovarian cancer. Clin Cancer Res. 11:3733–3742.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guşet G, Costi S, Lazăr E, Dema A,
Cornianu M, Vernic C and Păiuşan L: Expression of vascular
endothelial growth factor (VEGF) and assessment of microvascular
density with CD34 as prognostic markers for endometrial carcinoma.
Rom J Morphol Embryol. 51:677–682. 2010.PubMed/NCBI
|
|
41
|
Cantu De León D, Lopez-Graniel C, Frias
Mendivil M, Chanona Vilchis G, Gomez C and De La Garza Salazar J:
Significance of microvascular density (MVD) in cervical cancer
recurrence. Int J Gynecol Cancer. 13:856–862. 2003.PubMed/NCBI
|
|
42
|
Meresman G: Relevance of apoptosis in the
female reproductive system. Invest Clin. 52:274–290.
2011.PubMed/NCBI
|
|
43
|
Forones NM, Carvalho AP, Giannotti-Filho
O, Lourenço LG and Oshima CT: Cell proliferation and apoptosis in
gastric cancer and intestinal metaplasia. Arq Gastroenterol.
42:30–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Munkarah AR, Morris R, Baumann P, Deppe G,
Malone J, Diamond MP and Saed GM: Effects of prostaglandin E(2) on
proliferation and apoptosis of epithelial ovarian cancer cells. J
Soc Gynecol Investig. 9:168–173. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kumar S, Mahdi H, Bryant C, Shah JP, Garg
G and Munkarah A: Clinical trials and progress with paclitaxel in
ovarian cancer. Int J Womens Health. 2:411–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
